L
Lesley McGuffog
Researcher at University of Cambridge
Publications - 104
Citations - 14897
Lesley McGuffog is an academic researcher from University of Cambridge. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 47, co-authored 97 publications receiving 12479 citations. Previous affiliations of Lesley McGuffog include Latvian Biomedical Research and Study centre & University of Tasmania.
Papers
More filters
Journal ArticleDOI
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline Kuchenbaecker,Karoline Kuchenbaecker,John L. Hopper,Daniel R. Barnes,Kelly-Anne Phillips,T.M. Mooij,Marie-José Roos-Blom,Marie-José Roos-Blom,Sarah Jervis,Sarah Jervis,Flora E. van Leeuwen,Roger L. Milne,Roger L. Milne,Nadine Andrieu,David E. Goldgar,Mary Beth Terry,Matti A. Rookus,Douglas F. Easton,Antonis C. Antoniou,Lesley McGuffog,D. Gareth Evans,Daniel Barrowdale,Debra Frost,Julian Adlard,Kai-ren Ong,Louise Izatt,Marc Tischkowitz,Ros Eeles,Rosemarie Davidson,Shirley Hodgson,Steve Ellis,Catherine Noguès,Christine Lasset,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Jean-Pierre Fricker,Laurence Faivre,Pascaline Berthet,Maartje J. Hooning,Lizet E. van der Kolk,Carolien M. Kets,Muriel A. Adank,Esther M. John,Wendy K. Chung,Irene L. Andrulis,Irene L. Andrulis,Melissa C. Southey,Mary B. Daly,Saundra S. Buys,Ana Osorio,Christoph Engel,Karin Kast,Rita K. Schmutzler,Trinidad Caldés,Anna Jakubowska,Jacques Simard,Michael Friedlander,Sue-Anne McLachlan,Sue-Anne McLachlan,Eva Machackova,Lenka Foretova,Yen Y. Tan,Yen Y. Tan,Christian F. Singer,Edith Olah,Anne-Marie Gerdes,Brita Arver,Håkan Olsson +67 more
TL;DR: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location, a large cohort study recruited in 1997-2011 provides estimates of cancer risk based on BRCA1 and BRCa2 mutation carrier status.
Journal ArticleDOI
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
Hanne Meijers-Heijboer,Ans M.W. van den Ouweland,Jan Klijn,Marijke Wasielewski,Anja de Snoo,Rogier A. Oldenburg,Antoinette Hollestelle,M.M.J. Houben,Ellen Crepin,Monique M. van Veghel-Plandsoen,Fons Elstrodt,Cornelia M. van Duijn,C.C.M. Bartels,Carel Meijers,Mieke Schutte,Lesley McGuffog,Deborah J. Thompson,Douglas F. Easton,Nayanta Sodha,Sheila Seal,Rita Barfoot,Jon Mangion,Jenny Chang-Claude,Diana Eccles,Rosalind A. Eeles,D. Gareth Evans,Richard S. Houlston,Victoria Murday,Steven A. Narod,Tamara Peretz,Julian Peto,Julian Peto,Catherine M. Phelan,Hong Xiang Zhang,Csilla Szabo,Peter Devilee,David E. Goldgar,P. Andrew Futreal,Katherine L. Nathanson,Barbara L. Weber,Nazneen Rahman,Michael R. Stratton,Michael R. Stratton +42 more
TL;DR: The biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCa2 mutations, which is consistent with participation of the encoded proteins in the same pathway.
Journal ArticleDOI
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
Nazneen Rahman,Sheila Seal,Deborah J. Thompson,Patrick Kelly,Anthony Renwick,Anna Elliott,Sarah Reid,Katarina Spanova,Rita Barfoot,Tasnim Chagtai,Hiran Jayatilake,Lesley McGuffog,Sandra Hanks,D. Gareth Evans,Diana Eccles,Douglas F. Easton,Michael R. Stratton +16 more
TL;DR: The results show that PALB2 is a breast cancer susceptibility gene and further demonstrate the close relationship of the Fanconi anemia–DNA repair pathway and breast cancer predisposition.
Journal ArticleDOI
The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2
Sunil R. Lakhani,Marc J. van de Vijver,Jocelyne Jacquemier,Thomas J. Anderson,Peter Osin,Lesley McGuffog,Douglas F. Easton +6 more
TL;DR: The combined morphologic and immunohistochemical data can be used to predict the risk of a young patient harboring a germline mutation in BRCA1, and the BRC a2 phenotype is currently not well defined.
Journal ArticleDOI
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles
Sheila Seal,Deborah J. Thompson,Anthony Renwick,Anna Elliott,Patrick Kelly,Rita Barfoot,Tasnim Chagtai,Hiran Jayatilake,Munaza Ahmed,Katarina Spanova,Bernard North,Lesley McGuffog,D. Gareth Evans,Diana Eccles,Douglas F. Easton,Michael R. Stratton,Nazneen Rahman +16 more
TL;DR: Inactivating truncating mutations of BRIP1, similar to those in BRCA2, cause Fanconi anemia in biallelic carriers and confer susceptibility to breast cancer in monoallelic carriers.